Cargando…

Identification of lapatinib sensitivity-related genes by integrative functional module analysis

BACKGROUND: Globally, gastric carcinoma (GC) is one of the most commonly encountered malignancies and is the second highest contributor to cancer mortality. Lapatinib is a potent, orally-bioavailable small-molecule inhibitor of both epidermal growth factor receptor and human epidermal growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Qi-Hua, Liu, Guodong, Hu, Qiuhui, Wang, Jingwen, Leng, Kaiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799157/ https://www.ncbi.nlm.nih.gov/pubmed/35117483 http://dx.doi.org/10.21037/tcr.2020.01.30

Ejemplares similares

Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation
por: Aimjongjun, Sathid, et al.
Publicado: (2019)

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
por: Kancha, Rama Krishna, et al.
Publicado: (2011)

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib
por: Kankia, Ibrahim H., et al.
Publicado: (2017)

Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer
por: Bao, Shengnan, et al.
Publicado: (2020)

Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib
por: Showalter, Loral E., et al.
Publicado: (2019)

HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3
por: Chen, Jhen-Yu, et al.
Publicado: (2015)

Inhibition of Hes1 enhances lapatinib sensitivity in gastric cancer sphere-forming cells
por: Li, Luchun, et al.
Publicado: (2017)

EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer
por: Mahmud, Zimam, et al.
Publicado: (2019)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
por: Rana, Punam, et al.
Publicado: (2012)

Targeted treatment of advanced and metastaticbreast cancer with lapatinib
por: Corkery, Brendan, et al.
Publicado: (2008)

Development of the Rat Model of Lapatinib-Induced Diarrhoea
por: Bowen, Joanne M.
Publicado: (2014)

Lapatinib-induced acute generalized exanthematous pustulosis
por: Lakshmi, Chembolli, et al.
Publicado: (2010)

The concomitant use of lapatinib and paracetamol - the risk of interaction
por: Karbownik, Agnieszka, et al.
Publicado: (2018)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
por: Xie, Yizhao, et al.
Publicado: (2020)

LncRNAs GIHCG and SPINT1-AS1 Are Crucial Factors for Pan-Cancer Cells Sensitivity to Lapatinib
por: Xiang, Zhen, et al.
Publicado: (2019)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Lapatinib for the treatment of breast cancer in the People’s Republic of China
por: Wang, Hongjiang
Publicado: (2014)

Therapeutic Mechanism of Lapatinib Combined with Sulforaphane on Gastric Cancer
por: Yi, Huixing, et al.
Publicado: (2021)

Evaluation of Lapatinib-Loaded Microfibers Prepared by Centrifugal Spinning
por: Bitay, Enikő, et al.
Publicado: (2022)

Different chemical proteomic approaches to identify the targets of lapatinib
por: Kovačević, Tatjana, et al.
Publicado: (2023)

Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models
por: Formisano, Luigi, et al.
Publicado: (2014)

The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid
por: Karbownik, Agnieszka, et al.
Publicado: (2019)

ERRα activates SHMT2 transcription to enhance the resistance of breast cancer to lapatinib via modulating the mitochondrial metabolic adaption
por: Li, Xin, et al.
Publicado: (2020)

Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors
por: Chen, Yun-Ju, et al.
Publicado: (2013)

Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds
por: Katiyar, Samiksha, et al.
Publicado: (2013)

ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression
por: Qi, Leilei, et al.
Publicado: (2017)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2
por: West, N Winston, et al.
Publicado: (2013)

Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo
por: Liu, Hao, et al.
Publicado: (2023)

Lapatinib: the evidence for its therapeutic value in metastatic breast cancer
por: Thomson, Andrew
Publicado: (2005)

Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib
por: Oh, Byeongsang, et al.
Publicado: (2014)

Effects of lapatinib on cell proliferation and apoptosis in NB4 cells
por: Liu, Lu, et al.
Publicado: (2018)

Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib
por: Strickley, John D., et al.
Publicado: (2018)

Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites
por: de Sousa, Ana Carolina C., et al.
Publicado: (2020)

Correction: Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds
Publicado: (2014)

Lapatinib-induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro
por: Liao, Qiuyue, et al.
Publicado: (2020)

Lapatinib-induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro
por: Liao, Qiuyue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nv7jj1dt3vamc4jcp13vf53d3d